MEMPHASYS LTD (IG7) - Total Liabilities
Based on the latest financial reports, MEMPHASYS LTD (IG7) has total liabilities worth €5.59 Million EUR (≈ $6.54 Million USD) as of June 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore IG7 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
MEMPHASYS LTD - Total Liabilities Trend (2021–2024)
This chart illustrates how MEMPHASYS LTD's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see MEMPHASYS LTD balance sheet assets.
MEMPHASYS LTD Competitors by Total Liabilities
The table below lists competitors of MEMPHASYS LTD ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
YGL Convergence Bhd
KLSE:0086
|
Malaysia | RM3.59 Million |
|
Beowulf Mining PLC
ST:BEO-SDB
|
Sweden | Skr374.80K |
|
SG Blocks Inc
NASDAQ:SGBX
|
USA | $29.17 Million |
|
Starhedge SA
WAR:SHG
|
Poland | zł8.79 Million |
|
STREAMPLAY STUDIO LTD.
F:GIX0
|
Germany | €1.45 Million |
|
Fab-Form Industries Ltd.
V:FBF
|
Canada | CA$815.75K |
|
Ao World
LSE:AO
|
UK | GBX321.80 Million |
|
Teamo Productions HQ Limited
NSE:TPHQ
|
India | Rs173.29 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down MEMPHASYS LTD's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See IG7 net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.31 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.82 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.45 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how MEMPHASYS LTD's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for MEMPHASYS LTD (2021–2024)
The table below shows the annual total liabilities of MEMPHASYS LTD from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-06-30 | €5.59 Million ≈ $6.54 Million |
-23.21% |
| 2023-06-30 | €7.28 Million ≈ $8.51 Million |
+12.49% |
| 2022-06-30 | €6.47 Million ≈ $7.57 Million |
+8.38% |
| 2021-06-30 | €5.97 Million ≈ $6.98 Million |
-- |
About MEMPHASYS LTD
Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company offers Felix system, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, an in-vitro diagnostic device; and AI-Port, an ambie… Read more